Related Experiment Video

Updated: Aug 6, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non-amyloid Heart Failure and

Justin L Grodin1, Ahmad Masri2, Richard Wright3

  • 1University of Texas Southwestern Medical Center Dallas TX USA.

Journal of the American Heart Association
|July 25, 2026
PubMed

Insights

Transthyretin amyloid cardiomyopathy (ATTR-CM) significantly increases healthcare utilization and costs compared to non-amyloid heart failure (HF) and the general population. This progressive disease demands more hospitalizations and higher annual spending, highlighting its substantial economic burden.

Area of Science:

  • Cardiology
  • Health Economics
  • Epidemiology

Background:

  • Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal condition with significant healthcare costs.
  • Understanding the economic impact of ATTR-CM is crucial for resource allocation and patient management.

Purpose of the Study:

  • To compare healthcare resource utilization and costs in patients with ATTR-CM versus those with non-amyloid heart failure (HF) and controls without HF in the US.
  • To quantify the economic burden associated with ATTR-CM.

Main Methods:

  • Utilized Optum's de-identified Clinformatics Data Mart Database (2016-2023).
  • Identified ATTR-CM patients based on HF/cardiomyopathy claims within 2 years of ATTR diagnosis.
  • Matched ATTR-CM patients 1:1 with non-amyloid HF and non-HF controls using propensity score matching.

Main Results:

  • ATTR-CM patients experienced more all-cause hospitalizations (3.3 vs. 2.7 vs. 1.5 per patient) compared to non-amyloid HF and non-HF controls.
  • ATTR-CM patients had longer hospital stays and higher annual inpatient costs ($42,868 vs. $36,061 for non-amyloid HF).
  • Higher utilization and costs were observed in younger ATTR-CM patients, Black patients, and those in the Northeast/South regions.

Conclusions:

  • ATTR-CM is associated with significantly higher healthcare resource utilization and costs than non-amyloid HF and the general population.
  • The findings underscore the substantial economic burden of ATTR-CM, necessitating efficient management strategies.
Abstract

Keywords:
health care costshealth care resource utilizationheart failurehospitalizationsreal‐world datatransthyretin amyloid cardiomyopathy

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...